Optimus Healthcare Services (OTC PINK:OHCS) announced on June 15, 2021, that it has received FINRA approval for a corporate symbol change. The new ticker symbol, OHCS, will take effect on June 16, 2021.
This change aims to align the company's branding with its mission of creating a network of innovative healthcare entities focused on clinical research, disease management, and enhancing physician/patient interactions. CEO Marc Wiener emphasized the ongoing efforts to evaluate and acquire transformative healthcare businesses.
Optimus Healthcare Services, Inc. (OTC PINK:HOPS) announced its corporate name change, effective June 3, 2021, after receiving approval from FINRA. Previously known as 'Between Dandelions,' the company aims to better reflect its focus on healthcare services. CEO Marc Wiener stated that this change aligns with their growth strategy, which includes potential acquisitions and up-listing to a senior financial platform. Additionally, industry veteran Cliff Saffron has joined as Chief Financial Officer and General Counsel, reinforcing the company's strategic vision.
Optimus Healthcare Services, Inc. (HOPS) has successfully acquired AdhereRx, operating as PainScript, in a transaction valued at approximately $4.5 million as of March 24, 2021. CEO Dan Cohen will continue to lead PainScript while taking on the role of President at Optimus. This acquisition aims to enhance Optimus's portfolio in telehealth and chronic care compliance, particularly for Substance Use Disorder patients. The PainScript platform is currently in a beta phase and aims to formally launch its commercial version in the second half of 2021.
Optimus Healthcare Services (OTC PINK: HOPS), formerly Between Dandelions, Inc., announced a non-binding letter of intent to acquire PainScript, a SaaS-based telehealth platform for chronic care management. This acquisition aims to enhance care for patients with substance use disorders.
The deal is subject to due diligence and negotiation of a definitive agreement. Optimus expects the acquisition to advance its portfolio, reduce healthcare costs, and improve patient outcomes through PainScript's evidence-based compliance solutions.